

نظم توصيل دوائي دهنية للاستهداف المخي

رسالة مقدمة توطئة للحصول على درجة الماجستير في العلوم الصيدلانية (صيدلانيات)

كلية الصيدلة - جامعة عين شمس

اعداد

الصيدلانية / دينا محمد عبد الله داود

بكالوريوس في العلوم الصيدلانية - كلية الصيدلة - جامعة عين شمس

تحت اشراف

أ.د. حسين عثمان عمار

أستاذ التكنولوجيا الصيدلانية بالمركز القومي للبحوث

و رئيس قسم الصيدلانيات و التكنولوجيا الصيدلانية

جامعة المستقبل

أ.د. جيهان عبد السميع عوض

أستاذ الصيدلانيات والصيدلة الصناعية

كلية الصيدلة - جامعة عين شمس

أ.م.د. أماني اسامة كامل

مساعد الصيدلانيات والصيدلة الصناعية أستاذ

كلية الصيدلة - جامعة عين شمس

قسم الصيدلانيات والصيدلة الصناعية

كلية الصيدلة - جامعة عين شمس

2016

Lipid Drug Delivery Systems for Brain Targeting

*A thesis submitted in the partial fulfillment of the requirements for the
master degree of Pharmaceutical Sciences
(Pharmaceutics)*

By

Dina Mohamed AbdAllah Daoud

*Bachelor of Pharmaceutical Sciences, June 2008, Faculty of Pharmacy, Ain
Shams University.*

*Researcher Assistant of Pharmaceutical Technology, National Research
Center*

Under the Supervision of

Prof. Dr.Hussein Osman Ammar

*Professor of Pharmaceutical Technology,
National Research Center*

*Chairman, Department of Pharmaceutics and Pharmaceutical Technology,
Future University.*

Prof. Dr. Gehanne Abdel Samie Awad

*Professor of Pharmaceutics and Industrial Pharmacy,
Faculty of Pharmacy - Ain Shams University.*

Assoc.Prof.Dr.Amany Ossama Kamel

*Associate Professor of Pharmaceutics and Industrial Pharmacy
Faculty of Pharmacy - Ain Shams University*

*Department of Pharmaceutics and Industrial Pharmacy
Faculty of Pharmacy - Ain Shams University
Cairo 2016*

Acknowledgment

*First and foremost thanks to **ALLAH**, the Most Gracious and the Most Merciful, by the grace of whom this work was achieved. All praises to Allah for the strengths and His blessing in completing this thesis.*

*I would like to express my deep gratitude and sincere appreciation to **Prof. Dr. Hussein Osman Ammar**, Professor of Pharmaceutical Technology, National Research Center and Chairman, Department of Pharmaceutics and Pharmaceutical Technology, Future University, for his kind scientific supervision, suggestions, immense support, warm advices and fruitful reviewing of the thesis.*

*No words would ever express my sincerest appreciation to **Prof. Dr. Gehanne Abdel Samie Awad**, Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy - Ain Shams University, whom I owe so much for her valuable scientific supervision, abundant encouragement, indispensable help, continuous support and endless giving and sponsoring throughout the course of the presented study and preparation of the thesis. I have been extremely lucky to have a supervisor who cared so much about my work, and who responded to my questions and queries so promptly.*

*I am really thankful to **Assoc. Prof. Dr. Amany Ossama Kamel**, Associate Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy - Ain Shams University for her fruitful supervision and guidance.*

*I am profoundly grateful to **Prof. Dr. Ahmed Hassan El-Shafeey**, Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University for providing facilities for the in-vivo studies.*

*I would like to grab the opportunity to thank **Dr. Azza Ahmed Mahmoud**, Associate Professor of Pharmaceutical Technology, National Research Center, who stood by my side all the time, for her valuable advice, great effort and scientific support.*

*I would like to thank **Dr. Mona Abd El Motelb**, lecturer of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy - Ain Shams University for the help in the in-vivo studies.*

I would like to express my deep thanks to all my colleagues in the Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy - Ain Shams University, and at the National Research Center for their support.

*Special debt of gratitude is greatly acknowledged to my beloved mother **Dr. Nagwa Essmat** for her support, patience, love and encouragement during my whole life.*

*Extending gratitude to my dear husband **Dr. Khaled El Asmar** for his sincere support, help and encouragement. Thank you for giving me strength to reach for the stars and catch my dreams.*

*I would like to express my love to all my family members and to my little princess my daughter **Nada**.*

*I remember and express my gratitude to the **soul of my father** who was motivated when I joined Faculty of Pharmacy.*

Dina Mohamed Daoud

2016

Contents

Item	Page
List of Abbreviations	
List of Tables	
List of Figures	
Abstract	i
General Introduction	1
Scope of Work	25
Chapter I: Preliminary study for optimization of various formulation parameters for the preparation of anionic plain SLNs	
• Introduction	27
• Experimental	42
• Materials	42
• Apparatus	42
• Pre-formulation Screening	43
○ Preparation of plain SLNs	
▪ Lipid selection study for preparing SLNs	
▪ Method of preparation of SLNs	
▪ Characterization of the prepared plain SLNs	46
• Particle size analysis	
• Zeta Potential (ζ)	
• Results and Discussion	47
• Screening study	47
• Particle size and polydispersity index	48
• Zeta potential (ξ)	49
• Selected SLN Formulations	52
○ Particle size and poly dispersity index	
○ Zeta potential (ξ)	53
• Conclusion	57

Chapter II: Preparation and evaluation of Galantamine hydrobromide loaded anionic, cationic and chitosan SLNs	
• Introduction	58
• Experimental	61
• Materials	61
• Equipment	
• Methods	62
○ Preparation of medicated SLNs	62
○ Characterization of the prepared SLNs	65
▪ Morphology and surface properties	
• Dynamic Light Scattering Measurements	
• Transmission Electron Microscope (TEM)	
▪ Determination of entrapment efficiency (EE)	
○ Construction of calibration curves of GalHBr	
○ Calculation of GalHBr EE%	66
▪ <i>In vitro</i> Release Study of GalHBr from SLNs	65
▪ Differential scanning calorimetry	66
○ Statistical analysis	68
• Results and Discussion	69
▪ Calibration curve of GalHBr	69
▪ Effect of SDC-drug loading on particle size of SLNs	73
▪ Effect of SDC-drug loading on (ζ) of SLNs	73
▪ Effect of SDC - drug loading on PDI	74
▪ Effect of different factors on SDC-GalHBr SLNs characteristics	77
○ Particle size	77
○ Zeta Potential (ξ)	85
○ Poly dispersity index (PDI)	92
○ Entrapment efficiency (EE%)	92
○ <i>In vitro</i> drug release from GalHBr loaded SLNs	93
▪ Characterization of Cationic GalHBr SLNs	104
▪ Characterization of the chosen GalHBr loaded cationic SLNs	106
○ z-Average diameter	
○ Zeta Potential (ξ)	107

○ Entrapment efficiency (EE%)	107
○ <i>In-vitro</i> drug release from GalHBr loaded cationic SLNs	108
▪ Development and Optimization of Cs-SLNs	113
▪ Characterization of GalHBr loaded CS SLNs	116
▪ Transmission Electron Microscope (TEM)	123
▪ Differential Scanning Calorimetry (DSC)	126
• Conclusion	132
Chapter III: Biological studies on Galantamine Hydrobromide loaded anionic, cationic and chitosan SLNs formulations	
• Introduction	134
• Experimental	140
• Materials	140
• Animals	140
• Apparatus	140
• Methods	141
○ Assay of GalHBr in rat plasma and brain	141
▪ Chromatographic conditions	141
▪ Validation of the method	142
• Calibration curves for GalHBr in rat plasma and brain	142
○ Pharmacokinetic and brain transport studies	143
▪ Administration of GalHBr to rats	143
▪ Pharmacokinetic analysis	144
▪ Transport study using the <i>in-vivo</i> rat model	144
▪ Statistical analysis	145
○ Histopathological studies	145
• Results and Discussion	146
• LC-MS/MS method validation	146
• Pharmacokinetic and brain transport studies	151
○ Plasma pharmacokinetic parameters	151

○ Brain pharmacokinetic parameters	161
○ Transport study using in vivo rat model	170
• Histopathological studies	173
• Conclusion	177
Summary	179
References	185
Appendix I.	
Ethical committee approval for <i>in-vivo</i> studies	
Appendix II.	
Published paper	
Arabic Summary	

List of Abbreviations

AB	Absolute bioavailability
AD	Alzheimer's disease
ANOVA	Analysis of variance
APP	Amyloid precursor protein
AUC	Area under the curve
BBB	Blood Brain Barrier
BCSFB	Blood–cerebrospinal fluid barrier
C_{max}	Maximum concentration of drug
CMT	Carrier mediated transport
CNS	Central nervous system
CS	Chitosan
CSF	Cerebrospinal fluid
DLS	Dynamic light scattering
DSC	Differential scanning calorimetry
DTE	Drug targeting efficiency
DTP	Nose to brain direct transport percentage
EE	Entrapment efficiency
GalHBr	Galantamine hydrobromide
GMS	Glyceryl monostearate
GRAS	Generally regarded as safe
Grp	Group
HLB	Hydrophile-lipophile balance
HPLC	High performance liquid chromatography
IN	Intranasal
IS	Internal standard
IV	Intravenous
LC-MS/MS	Liquid chromatography tandem mass spectrometry
min	Minutes
MRT	Mean residence time

NA	Not applicable
NLCs	Nanostructured lipid carriers
NPs	Nanoparticles
PBS	Phosphate buffer saline
PDI	Polydispersity index
P-gp	P-glycoprotein
Plx1888	Poloxamer188
PS	Particle size
RE	Release efficiency
RMT	Receptor mediated transport
rpm	Rotation per minute
SA	Stearylamine
SD	Standard deviation
SDC	Sodium deoxycholate
SE	Standard error
SLNs	Solid lipid nanoparticles
t_{1/2}	Half life time
TEM	Transmission electron microscope
Tf	Transferrin
TJs	Tight junctions
T_{max}	Time of occurrence of maximum drug concentration
UV	Ultraviolet
w/o	Water in oil
w/w	Weight per weight
ζ	Zeta potential
λ_{max}	Wavelength of maximum absorbance

List of Tables

No.	Table title	Page
1	Composition of plain SLNs prepared with different lipids in presence of Tween80 or Brij [®] 78 (3% w/w)	44
2	Composition of plain SLNs prepared using 7.5% (w/w) different lipids in presence of different surfactant concentrations	45
3	Mean PS, PDI and ζ of formulations prepared with Tween80 (3%)	50
4	Mean PS, PDI and ζ of formulations prepared with Brij [®] 78 (3%)	51
5	Physicochemical properties of plain SLNs prepared using 7.5% of various lipids in presence of different surfactant concentrations	54
6	Factors and levels used in the factorial design for the preparation of GalHBr loaded SLNs.	63
7	Composition of different GalHBr loaded SLNs according to the established factorial design	64
8	Composition of Cationic GalHBr SLNs	64
9	Composition of Cationic GalHBr SLNs containing chitosan	64
10	Data of the calibration curve for spectrophotometric determination of GalHBr in distilled water at 288.8 nm.	70
11	Data of the calibration curve for spectrophotometric determination of GalHBr in phosphate buffer saline (PBS) at 288.6 nm.	71
12	Composition, Particle size, PDI, ZP and EE% of GalHBr loaded SLNs prepared according to factorial design.	76
13	ANOVA table for the particle size of GalHBr loaded SLNs	78
14	ANOVA table for the zeta potential of GalHBr loaded SLNs	86
15	In vitro release data of GalHBr from SLNs in PBS PH=6.8	94
16	Release efficiency % (RE%) of GalHBr loaded SLNs	99
17	Kinetic parameters for GalHBr release from SLNs	100
18	Effect of different concentrations of SA on the measured physical properties of GalHBr loaded SLNs	105
19	Effect of increasing SDC concentration on the measured physical properties of GalHBr loaded cationic SLNs prepared with 0.56% SA.	105

20	The physicochemical properties and EE% of GalHBr loaded cationic SLNs	106
21	In vitro release data of GalHBr from cationic SLNs in PBS PH=6.8	109
22	Release efficiency % of GalHBr loaded cationic SLNs	110
23	Kinetic parameters for GalHBr release from cationic SLNs	111
24	Physicochemical properties of blank CS-SLNs	115
25	The physicochemical properties and EE% of GalHBr loaded cationic and CS SLNs	117
26	In vitro release data of GalHBr from CS SLNs in PBS PH=6.8	119
27	Release efficiency % of GalHBr loaded cationic and CS SLNs	122
28	Kinetic parameters for GalHBr release from CS SLNs	122
29	Order of release of GalHBr loaded cationic and CS SLNs	122
30	The endothermic peaks of the used excipients and their enthalpy values	127
31	Relation between GalHBr concentration and the peak area ratio of GalHBr / IS in spiked rat plasma and brain	149
32	Plasma GalHBr concentrations in rats receiving IV GalHBr solution (group 1)	154
33	Plasma GalHBr concentrations in rats receiving IN GalHBr solution (group 2)	154
34	Plasma GalHBr concentrations in rats receiving IN GalHBr loaded anionic SLNs F20 (group 3)	155
35	Plasma GalHBr concentrations in rats receiving IN GalHBr loaded cationic SLNs F20S (group 4)	155
36	Plasma GalHBr concentrations in rats receiving IN GalHBr loaded chitosan SLNs F20SCS (group 5)	156
37	Mean plasma GalHBr concentrations in different groups of rats	157
38	Plasma pharmacokinetic parameters for GalHBr following IV and IN administration of solutions and different formulations in rats	158
39	Brain GalHBr concentrations in rats receiving IV GalHBr solution (group 1)	163
40	Brain GalHBr concentrations in rats receiving IN GalHBr solution (group 2)	163
41	Brain GalHBr concentrations in rats receiving IN GalHBr loaded anionic SLNs F20 (group 3)	164

42	GalHBr concentrations in brain of rats receiving IN GalHBr loaded cationic SLNs F20S (group 4)	164
43	Brain GalHBr concentrations in rats receiving IN GalHBr loaded chitosan SLNs F20SCS (group 5)	165
44	Mean brain GalHBr concentrations in different groups of rats	166
45	Brain pharmacokinetic parameters for GalHBr following IV and IN administration of solutions and different formulations in rats	167
46	DTE%, DTP% and BBR for rats receiving IN GalHBr SLNs (Grps 2 – 5)	171